GlassScriptPhysician profile
Howard D Lipkin
NPI 1326130592
$58,113.54
in general payments reported to CMS, 2019-2025
26 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $6,076 · 2021: $8,346 · 2022: $27K · 2023: $16K · 2024: $144 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $954 · Travel and Lodging: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,969.40 |
| Food and Beverage | $953.85 |
| Travel and Lodging | $520.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38,160.71 | 2019-2022 | |
| Abbvie INC. | $16,232.67 | 2020-2025 | |
| Janssen Biotech, INC. | $701.12 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $608.06 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $562.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $238.73 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $232.99 | 2020-2023 | Dupixent |
| Leo Pharma INC. | $187.91 | 2019-2022 | |
| Pfizer INC. | $182.81 | 2020-2023 | |
| Incyte Corporation | $152.18 | 2022-2023 | Opzelura |
| Genzyme Corporation | $150.33 | 2022-2025 | |
| Revance Therapeutics, INC. | $143.96 | 2024 | Daxxify |
| Genentech USA, INC. | $138.91 | 2019-2022 | |
| Amgen INC. | $82.37 | 2022 | |
| Biofrontera INC. | $72.42 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $48.83 | 2021-2023 | Cimzia |
| Strata Skin Sciences, INC. | $40.85 | 2019-2025 | Xtrac |
| Vyne Pharmaceuticals INC. | $38.25 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $24.44 | 2023 | |
| Verrica Pharmaceuticals INC. | $19.83 | 2025 | Ycanth |
| Almirall LLC | $19.76 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.10 | 2021 | |
| Dermavant Sciences, INC. | $15.80 | 2023 | Vtama |
| Journey Medical Corporation | $15.78 | 2022 | |
| Prugen, INC. Pharmaceuticals | $13.79 | 2019 | |
| Mayne Pharma Commercial LLC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Lipkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.